Skip to Content

Silver sulfadiazine topical Pregnancy and Breastfeeding Warnings

Silver sulfadiazine topical is also known as: SSD, SSD AF, Silvadene, Silvadene Cream 1%, Thermazene

Silver sulfadiazine topical Pregnancy Warnings

Animal studies have failed to reveal evidence of fetal harms. Sulfonamides may cause kernicterus in patients during the first month of life by displacing bilirubin from plasma albumin. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

Use is not recommended unless clearly needed, especially in pregnant women approaching or at term. -According to some authorities: Use should be avoided during the last month of pregnancy. AU TGA pregnancy category: C US FDA pregnancy category: B

See references

Silver sulfadiazine topical Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: The effects in the nursing infant are unknown.

Sulfonamides are known to be excreted in human milk and all sulfonamide derivatives are known to increase the possibility of kernicterus. There is a possibility for serious adverse reactions in nursing infants from sulfonamides.

See references

References for pregnancy information

  1. "Product Information. Silvadene (silver sulfadiazine topical)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

References for breastfeeding information

  1. "Product Information. Silvadene (silver sulfadiazine topical)." Pfizer U.S. Pharmaceuticals Group, New York, NY.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.